AR105561A1 - ANTIBODY CONSTRUCTS FOR THE KINASE TIROSINE RECEIVER (FLT3) AND CD3 ANTIGEN - Google Patents
ANTIBODY CONSTRUCTS FOR THE KINASE TIROSINE RECEIVER (FLT3) AND CD3 ANTIGENInfo
- Publication number
- AR105561A1 AR105561A1 ARP160102340A ARP160102340A AR105561A1 AR 105561 A1 AR105561 A1 AR 105561A1 AR P160102340 A ARP160102340 A AR P160102340A AR P160102340 A ARP160102340 A AR P160102340A AR 105561 A1 AR105561 A1 AR 105561A1
- Authority
- AR
- Argentina
- Prior art keywords
- flt3
- antibody construct
- tirosine
- kinase
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente se refiere a un constructo de anticuerpo biespecífico que comprende un primer dominio de unión que se une a FLT3 humana en la superficie de una célula diana y un segundo dominio de unión que se une a CD3 humano en la superficie de una célula T. Además, se provee un polinucleótido que codifica el constructo de anticuerpo, un vector que comprende dicho polinucleótido y una célula hospedante transformada o transfectada con dicho polinucleótido o vector. Adicionalmente, se provee un proceso para la producción del constructo de anticuerpo, un uso médico de dicho constructo de anticuerpo y un kit que comprende dicho constructo de anticuerpo.This refers to a bispecific antibody construct comprising a first binding domain that binds to human FLT3 on the surface of a target cell and a second binding domain that binds to human CD3 on the surface of a T cell. In addition, a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector is provided. Additionally, a process for the production of the antibody construct, a medical use of said antibody construct and a kit comprising said antibody construct is provided.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562199944P | 2015-07-31 | 2015-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR105561A1 true AR105561A1 (en) | 2017-10-18 |
Family
ID=60245275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160102340A AR105561A1 (en) | 2015-07-31 | 2016-08-01 | ANTIBODY CONSTRUCTS FOR THE KINASE TIROSINE RECEIVER (FLT3) AND CD3 ANTIGEN |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR105561A1 (en) |
MA (1) | MA42532B1 (en) |
-
2016
- 2016-08-01 MA MA42532A patent/MA42532B1/en unknown
- 2016-08-01 AR ARP160102340A patent/AR105561A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
MA42532B1 (en) | 2023-05-31 |
MA42532A (en) | 2018-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018000882A2 (en) | Antibody constructs for flt3 and cd3 | |
CO2018000976A2 (en) | Antibody constructs for cd70 and cd3 | |
CO2018000887A2 (en) | Bispecific antibody constructs that bind to egfrviii and cd3 | |
CO2018000885A2 (en) | Bispecific antibody constructs that bind mesothelin and cd3 | |
CO2018000877A2 (en) | Bispecific antibody constructs that bind dll3 and cd3 | |
AR101669A1 (en) | ANTIBODY CONSTRUCTS FOR CDH19 AND CD3 | |
BR112018015670A2 (en) | Bispecific t-cell antibody constructs | |
CL2017002641A1 (en) | Bispecific antibody constructs against cdh3 and cd3 | |
AR105561A1 (en) | ANTIBODY CONSTRUCTS FOR THE KINASE TIROSINE RECEIVER (FLT3) AND CD3 ANTIGEN | |
AR105562A1 (en) | ANTIBODY CONSTRUCTS FOR RECEIVER OF THE VARIANT EPIDERMAL GROWTH FACTOR VIII (EGFRVIII) AND THE ANTIGEN CD3 | |
AR105559A1 (en) | ANTIBODY CONSTRUCTS FOR CD70 AND CD3 | |
AR105558A1 (en) | ANTIBODY CONSTRUCTS FOR DLL3 AND CD3 | |
AR105560A1 (en) | ANTIBODY CONSTRUCTS FOR MSLN AND CD3 | |
AR113854A1 (en) | ANTI-CXCR5 ANTIBODIES, COMPOSITIONS AND USES THEREOF |